This appointment, which represents a new position on the board, brings the total number of company directors to nine, with six serving independently. Current chairman Gregory Pusey is becoming the company’s vice chairman, also a new position.
Mr Faulkner most recently served as president, CEO and member of the board of directors of Digene. Prior to joining Digene, Mr Faulkner spent eight years with Invitrogen in a number of senior roles, including senior vice president (SVP) Europe, SVP IVGN international operations, and SVP of strategic business units.
Gregory Pusey, chairman of AspenBio Pharma, said: “Daryl’s long record as an industry leader in creating shareholder value through the development and commercialization of important medical products bodes well for AspenBio. We look forward to working closely with Daryl as AspenBio continues to advance its many opportunities.”